The Osteoarthritis Research Society International's World Congress on Osteoarthritis concluded on April 21, with a clear focus on finding new ways to recognize the disease early and identify and slow progression.
Conferences page on Musculoskeletal Network features reports on the latest in osteoarthritis research, including:
New in the nonspecialty journals: A new option for patients with autoimmune disease and HCV infection. The value of combined therapy for osteoporosis. Prognosis predictors for chronic pain, a new opioid adverse effect, and more ... More »
A 39-year-old woman, in her eighth week of pregnancy, experienced aching pain that worsened with activity. Weakness and fatigue set in three days later in her thigh and proximal arm muscle. Then a mildly pruritic rash developed across the forehead, nose, and forearms. More »
Some patients with systemic lupus erythematosus or antiphospholipid syndrome may initially present with movement disorders, especially chorea. Physicians may not associate these symptoms with either disorder, thereby delaying diagnosis and effective treatment. More »
The latest results from two late-stage, multicenter clinical trials of belimumab (Benlysta) show that, when given alongside standard therapy for systemic lupus erythematosus, the drug improves health-related quality of life (HRQOL) and fatigue. More »
We routinely treat disorders such as rheumatoid arthritis, lupus, scleroderma, and ankylosing spondylitis with immunosuppressive drugs. Yet if infection were known to be the root cause, this course of action would seem counterintuitive, if not potentially dangerous in the short or long run. More »
Osteoporosis is a common problem in thalassemics. As the most affected bone is spinal vertebrae, theoretically, it should have the greatest risk of fracture. However, vertebral fracture (VF) in thalassemics was rarely reported. Screening for asympt
Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has not been published. The purpose of this retrospective cohort study was to eval
This is the main page for the National Institute of Arthritis and Musculoskeletal and Skin Diseases, one component of the National Institutes of Health, part of the U.S. Department of Health and Human Services.
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
(AUDIO) Data from a long-term prospective study reveal that, for many older women, the pace of bone mass deterioration takes place on the scale of decades, not single years. Here, the lead author of the study describes how to interpret the results to choose the date for your patient's next bone-density test.